Clinical and MRI correlates of CSF neurofilament light chain levels in relapsing and progressive MS.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
May 2019
Historique:
received: 10 09 2018
revised: 01 02 2019
accepted: 03 02 2019
pubmed: 18 2 2019
medline: 10 8 2019
entrez: 18 2 2019
Statut: ppublish

Résumé

A major aim in MS field has been the search for biomarkers that enable accurate detection of neuronal damage. Besides MRI, recent studies have shown that neuroaxonal damage can also be tracked by neurofilament detection. Nevertheless, before widespread implementation, a better understanding of the principal contributors for this biomarker is of paramount importance. Therefore, we analyzed neurofilament light chain (NfL) in relapsing (RMS) and progressive MS (PMS), addressing which MRI and clinical variables are better related to this biomarker. Forty-seven MS patients underwent MRI (3T) and cerebrospinal fluid (CSF) sampling. We measured NfL concentrations using ELISA (UmanDiagnostics) and performed multivariable regression analysis to assess the contribution of clinical and MRI metrics to NfL. NfL correlated with previous clinical activity in RMS (p < 0.001). In RMS, NfL also correlated with Gad+ and cortical lesion volumes. However, after multivariable analysis, only cortical lesions and relapses in previous 12 months remained in the final model (R CSF NfL levels are increased in RMS and associated with relapses and cortical lesions. Although NfL levels were correlated with Gad+ lesion volume, this association did not persist in multivariable analysis after controlling for previous clinical activity. We encourage controlling for previous clinical activity when testing the association of NfL with MRI. In PMS, the major contributor to NfL was T1-hypointense lesion volume.

Identifiants

pubmed: 30772673
pii: S2211-0348(19)30060-4
doi: 10.1016/j.msard.2019.02.004
pii:
doi:

Substances chimiques

Biomarkers 0
Neurofilament Proteins 0
neurofilament protein L 0

Types de publication

Journal Article

Langues

eng

Pagination

149-153

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Alfredo Damasceno (A)

Department of Neurology, University of Campinas (UNICAMP), Campinas, Brazil; Neuroimmunology Unit, Department of Genetics, Evolution and Bioagents, University of Campinas (UNICAMP), Campinas, Brazil. Electronic address: alfredodamasceno@hotmail.com.

Rafael Paterno C Dias-Carneiro (RPC)

Neuroimmunology Unit, Department of Genetics, Evolution and Bioagents, University of Campinas (UNICAMP), Campinas, Brazil.

Adriel Santos Moraes (AS)

Neuroimmunology Unit, Department of Genetics, Evolution and Bioagents, University of Campinas (UNICAMP), Campinas, Brazil.

Vinícius O Boldrini (VO)

Neuroimmunology Unit, Department of Genetics, Evolution and Bioagents, University of Campinas (UNICAMP), Campinas, Brazil.

Raphael Patrício S Quintiliano (RPS)

Neuroimmunology Unit, Department of Genetics, Evolution and Bioagents, University of Campinas (UNICAMP), Campinas, Brazil.

Verônica Almeida de Paula Galdino da Silva (VAPG)

Neuroimmunology Unit, Department of Genetics, Evolution and Bioagents, University of Campinas (UNICAMP), Campinas, Brazil.

Alessandro S Farias (AS)

Neuroimmunology Unit, Department of Genetics, Evolution and Bioagents, University of Campinas (UNICAMP), Campinas, Brazil.

Carlos Otavio Brandão (CO)

Neuroimmunology Unit, Department of Genetics, Evolution and Bioagents, University of Campinas (UNICAMP), Campinas, Brazil.

Benito Pereira Damasceno (BP)

Department of Neurology, University of Campinas (UNICAMP), Campinas, Brazil.

Leonilda Maria Barbosa Dos Santos (LMB)

Neuroimmunology Unit, Department of Genetics, Evolution and Bioagents, University of Campinas (UNICAMP), Campinas, Brazil.

Fernando Cendes (F)

Department of Neurology, University of Campinas (UNICAMP), Campinas, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH